{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"The incidence of grade 2-4 acute GVHD (Graft Versus Host Disease) by day 100\n\nGrade 2 GVHD: Maculopapular rash covering 25-50% of BSA (Body Surface Area), bilirubin between 3.1-6 mg/dl, and/ or adult stool output between 1000-1500 ml/day (child between 20-30 ml/kg/day).\n\nGrade 3 GVHD: Maculopapular rash covering \\>50% of BSA, bilirubin between 6.1-15 mg/dl, and/ or adult stool output \\>1500 ml/day (child \\>30 ml/kg/day).\n\nGrade 4 GVHD: Generalized erythroderma plus bullous formation and desquamation \\>5% BSA, bilirubin \\>15 mg/dl, and/ or severe abdominal pain with or without ileus, or grossly bloody stool.","groups":[{"description":"Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180. Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.","id":"OG000","title":"Supportive Care (Vorinostat, Tacrolimus, Methotrexate)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 100","title":"The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100","type":"PRIMARY","unitOfMeasure":"participants"}